The results of a randomized, open-label, and blinded trial of tenecteplase vs. alteplase (tissue plasminogen activator) for thrombolysis in patients with acute ischemic stroke are now published in full in the March 22 issue of the New England Journal of Medicine (N. Engl. J. Med. 2012;366:1099-1107). We previously reported on the results of the trial when they were presented at this year’s International Stroke Conference. (See "Related News" item at left.) The full paper does not contain any notable revisions from our original report.